One of the most common surprises in supplement development happens after the formula is finalized, the label is drafted, and the launch date is set: someone asks whether an ingredient needs a New Dietary Ingredient (NDI) notification, and nobody has a confident answer. Getting this question right early saves months later.
Under the Dietary Supplement Health and Education Act (DSHEA), a dietary ingredient is treated as "grandfathered" if it was marketed in the United States as a dietary ingredient in a dietary supplement before October 15, 1994. Ingredients that clear that bar — many common vitamins, minerals, amino acids, and long-used botanicals — generally don't require a notification. Anything that doesn't clear it is, by definition, a New Dietary Ingredient, and its use in a supplement generally must be supported by a notification to the FDA before the product goes to market, unless the ingredient has been present in the food supply as an article used for food, in a form that hasn't been chemically altered.
A point of confusion worth clearing up: GRAS (Generally Recognized As Safe) status is a food-additive concept, not a dietary-supplement one. An ingredient that's GRAS for use in a beverage or snack food is not automatically cleared for use as a dietary ingredient in a capsule or powder. The two frameworks ask different questions and are reviewed under different legal standards, so a GRAS letter alone doesn't substitute for an NDI analysis.
Several things commonly trigger the need for a fresh notification even when a brand assumes an ingredient is "already established." A new extraction method or solvent, a novel plant part (root versus leaf, for example), a new salt or ester form, a nanoparticle or other altered particle-size delivery format, or a meaningfully different concentration or ratio of constituents can all count as a new dietary ingredient in the eyes of the agency, even if a related version of the ingredient has circulated in the market for years. This is why two products with similar-sounding labels can sit on opposite sides of the notification requirement.
What the notification itself has to establish is straightforward in concept, demanding in execution. It needs to identify the ingredient precisely — its source, manufacturing process, and specifications — and it needs to present evidence that the ingredient will reasonably be expected to be safe under the conditions of use described on the label, including the intended dose and duration of use. That evidence can draw on history of safe human use, published toxicology or clinical data, animal studies, or a combination of these, but it has to be assembled and presented in a way that speaks directly to the specific form and intake level being marketed, not just the ingredient in general.
Timing is where this issue reshapes a launch plan. The notification has to be submitted at least 75 days before the ingredient is introduced into interstate commerce, and that clock only starts once the submission is complete. If the FDA raises questions or objects, the brand either has to satisfy those concerns or step back and reformulate — either path adds real time. Add in the weeks or months needed to compile a defensible safety dossier, and a brand that discovers late in development that its "signature" botanical extract needs a notification can watch a six-month launch plan stretch well past a year.
The practical fix is to treat this as a formulation-stage question, not a labeling-stage one. Every unique ingredient, extraction method, and delivery form in a formula should be checked against its history of marketed use before development goes much further. Where the answer is unclear, it's worth checking whether another company has already filed a notification for a comparable ingredient and use — while that filing doesn't automatically clear a new brand's use, it does help gauge what kind of safety evidence FDA has previously expected. A contract manufacturer that works across many ingredient categories can often help a brand assemble the specifications, manufacturing documentation, and use history needed to make that determination early, before it becomes a bottleneck.
The underlying goal of the NDI framework is simple even though the process isn't: new ingredients entering the supplement supply should have some demonstrated basis for safety before they reach consumers. Brands that plan around that reality — rather than discovering it during a compliance review — are the ones that hit their launch windows.
